LUNG CANCER, NONSMALL CELL
Clinical trials for LUNG CANCER, NONSMALL CELL explained in plain language.
Never miss a new study
Get alerted when new LUNG CANCER, NONSMALL CELL trials appear
Sign up with your email to follow new studies for LUNG CANCER, NONSMALL CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple drug cocktail shows promise against tough lung cancer
Disease control OngoingThis study is testing whether a combination of three drugs—nivolumab, ipilimumab, and nintedanib—can safely shrink tumors in people with advanced non-small cell lung cancer that has no curative options. The trial involves 66 participants and is split into two phases: the first fi…
Matched conditions: LUNG CANCER, NONSMALL CELL
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Scientists probe how lung cancer outsmarts key drugs
Knowledge-focused OngoingThis study looks at why lung cancer cells stop responding to a class of drugs called EGFR inhibitors. Researchers will collect blood samples from 80 patients over time to track changes in tumor DNA and cells. The goal is to understand the early steps of drug resistance and find w…
Matched conditions: LUNG CANCER, NONSMALL CELL
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Blood markers may reveal which lung cancer patients stay Cancer-Free after treatment
Knowledge-focused OngoingThis study follows 23 people with advanced non-small cell lung cancer who have finished at least 20 months of immunotherapy. Researchers collect blood and tissue samples to look for DNA and immune system markers that might predict if the cancer will come back within 6 months. The…
Matched conditions: LUNG CANCER, NONSMALL CELL
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Tiny study probes risks of lung cancer combo therapy
Knowledge-focused OngoingThis study followed 12 people with stage IV non-small cell lung cancer who received both palliative chest radiation and an immunotherapy drug (nivolumab or pembrolizumab). The goal was to track side effects like radiation-related toxicities and patient quality of life. Researcher…
Matched conditions: LUNG CANCER, NONSMALL CELL
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC